Advanced Biological Laboratories (ABL), S.A., is a diagnostic and medical software company founded in 2000 as a spin-off from CRP-Santé ( Luxembourg.

ABL’s products offer to infectious disease clinicians, virology and microbiology laboratories.

· Assays and standalone software systems for accredited laboratories (i.e. ISO 15189), mainly for microbiology applications (related to HIV, SARS-CoV-2, Tuberculosis, HCV, HBV, HPV, CMV, HPV, Flu, 16s RNA…) for clinical genotyping through sequencing (DeepChek®), DNA and RNA detection and quantification (UltraGene®), including powerful downstream analysis software applications fully integrated with knowledge databases and analysis systems for capillary and high-throughput Next Generation Sequencing data.

· Clinical software applications for infectious diseases units

· IT dashboards and clinical database aggregation applications for research

ABL took in 2013 the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL as well as a personalized medicine electronic medical record system (EMR) in infectious disease from GlaxoSmithKline in 2016. In July 2018, acquired CDL Pharma to develop CRO related services and assays manufacturing capacity.

In September 2022, ABL France became ABL Diagnostics and listed on Euronext Paris Midcap market. Since 2019, ABL gave the mission to ABL France, its 100% owned affiliate, to design, develop, manufacture, and market IVD medical devices for some of its RUO products, especially for HIV-1 as the software components exist. ABL Diagnostics site was certified ISO 13485 in October 2022.

In December 2022, ABL acquired a medical device company in Germany, Humedics GmbH, which is dedicated to the management of patients having liver transplantation and who need liver function assessments.

ABL has a comprehensive suite of healthcare management products, including Nadis®, ViroScore®, SeqHepB, DeepChek®, UltraGene®, BacterioChek and MicrobioChek used for data and patient management, monitoring and personalized reporting applications.

Since 2020, ABL got some CE-IVD marking for its DeepChek assays and its UltraGene assays. The other products are currently available for Research Use Only.

ABL S.A Group




And since December 2022,